Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited tools at their disposal to predict who is most likely to benefit or suffer from a particular myeloma therapy. These findings are reported in a recent study published in the European Journal of Haematology, in which the authors present a comprehensive review of the field. The study maps the current approaches to prediction in multiple myeloma, highlighting what is missing and outlining the path forward for truly personalized care of cancer patients.
This article was originally published on MedicalXpress.com
